Entrepreneur Noor Shaker only moved into health care in 2017, after pursuing an academic career in computer science and artificial intelligence that focused on gaming and adaptive artificial intelligence (AI). She is already making her mark. Her latest start-up, GlamorousAI, was launched into the coronavirus pandemic and quickly established a collaboration with Cardiff University in the UK to design a novel compound to treat COVID-19. The five-person firm is also working on additional projects with academic, biotech and pharma partners.
Gaming Whiz Brings AI Smarts To Drug Discovery
Machine Learning Opens Windows On New Disease Targets
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
More from Leadership
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.